News | October 10, 2013

Biotronik Launches Idova 7 ICD, Approved for MR Scanning

First worldwide implantations of the ultrahigh-energy device taking place in Italy and Austria

Biotronik Inc Idova 7 ICD MRI EP Lab Austria Italy

October 10, 2013 — Biotronik announced the launch of the new Idova 7 series. Idova 7 ICDs (implantable cardioverter-defibrillators) and CRT-Ds (cardiac resynchronization therapy defibrillators) offer ultrahigh-energy therapy without compromising on short charge times (10 seconds), smaller size (34 cc) and longevity of more than 11 years. Designed to stop life-threatening arrhythmias with the very first shock, Idova 7 gives patients valuable peace of mind.

As the only device on the market approved for (magnetic resonance imaging) MRI that is also able to offer 45 joule, Idova 7 is engineered to increase the success rate of the first shock and reduce the need for subsequent shocks. Idova 7 therefore enhances security for doctors and patients, offering them the promise of successful therapy from the very beginning.

“Ideally, a patient’s heart would react the same way to ICD therapy in real life as it would when tested after implantation. But that is not so often the case,” commented Dr. Clemens Steinwender, General Hospital Linz, Austria. “If I can give my patients that extra energy at the first shock, then I can assure them they are on the safe side.”

For ICD therapy to be successful, it is crucial to be aware of a patient’s defibrillation threshold (DFT), defined as the amount of energy required to shock the heart back to a normal rhythm. But DFT has a tendency to rise over time, and require higher amounts of energy. Higher DFTs can be caused by factors as widespread as prescribed medication, severely dilated hearts or young age and high activity levels.

“There are many variables that are related to the patient’s health and lifestyle, and not under my direct control. These can unfortunately affect defibrillation thresholds without our advanced knowledge,” explained Dr. Fabrizio Caravati, Hospital Fondazione Macchi of Varese, Italy. “It is important to be able to reassure patients that they have the maximum amount of energy at their disposal, in the event they should need it,” continued Dr. Paolo Bonfanti, Hospital Fondazione Macchi of Varese, Italy.

“After launching Ilesto and Iforia, we can now broaden our second generation of ProMRI devices with the ultrahigh-energy Idova 7 series,” commented Christoph Böhmer, president international at Biotronik. “Like all innovative Biotronik implants, Idova 7 will also be available with Biotronik Home Monitoring, which rapidly detects clinically relevant events like arrhythmias and can thereby prevent stroke and reduce hospitalization. In fact, the results of the recent IN-TIME study, introduced at this year’s ESC conference, demonstrated a significant reduction in all-cause mortality in heart failure patients with implant-based remote monitoring.”

For more information:

Related Content

Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Technavio Projects 9 Percent Global Growth for Electrophysiology Therapeutic Devices

Image courtesy of Technavio

News | EP Lab| September 11, 2017
September 11, 2017 — According to the latest market study released by Technavio, the global...
EMANATE Trial Shows Apixaban Lowers stroke in AF Patients Undergoing Cardioversion.
News | Atrial Fibrillation| September 01, 2017
September 1, 2017 — Apixaban lowers the risk of stroke compared to warfarin in anticoagulation-naïve patients with at
CASTLE-AF Study shows Catheter Ablation of Atrial Fibrillation is First-Line Treatment for Heart Failure Patients. Biotronic Ilivia 7 ICD.

The CASTLE-AF Study shows catheter alation of AF can be used effectively to treat heart failure in patients with an implanted ICD.

News | Atrial Fibrillation| September 01, 2017
September 1, 2017 — Final results from the CASTLE-AF study show a 38 percent reduction in the composite of all-cause
GE Healthcxare Signa Pioneer MAGIC six contrasts in one scan software by SyntheticMR.

The MRI software enables several different contrasts to be obtained from one scan, shortening scan times.

Feature | Magnetic Resonance Imaging (MRI)| August 31, 2017
August 31, 2017 — The U.S. Food and Drug Administration (FDA) has granted market clearance for SyntheticMR’s SyMRI.
Abbott. St. Jude Medical has updated its firmware to address cybersecurity issues with its Allure Quadra MP and other EP devices

Abbott. St. Jude Medical has updated its firmware to address cybersecurity issues with its Allure Quadra MP and other EP devices.

Feature | EP Lab| August 29, 2017 | Dave Fornell
August 29, 2017 — The U.S.
European Medicines Agency Issues Update on Gadolinium Contrast Agents
News | Contrast Media| August 29, 2017
August 29, 2017 — The European Medicines Agency (EMA) issued a final opinion that recommended restricting the use of
Biotronik Announces U.S. Launch of Edora HF-T QP CRT Pacemaker
Technology | Cardiac Resynchronization Therapy Devices (CRT)| August 21, 2017
Biotronik announced U.S. Food and Drug Administration (FDA) approval and commercial availability of Edora HF-T QP, an...
Houston Methodist Hospital Enters Multi-Year Technology and Research Agreement With Siemens Healthineers
News | Cardiac Imaging| August 17, 2017
Houston Methodist Hospital and Siemens Healthineers have entered into a multi-year agreement to bring cutting-edge...
Overlay Init